Frontier Ip Share Discussion Threads

[newtothisgame3] 01/4/2019 21:08

#FIPP #Frontier #IP say good results will pave the way for greater growth

[uk2day] 27/3/2019 19:57

Nice results!! Onwards we go!!!!

[best1467] 25/2/2019 07:03

Plenty of new antibiotics been discovered Paratek just had two passed by FDA and number more in pipeline albeit in different area.
I’m surprised we have had no news on the Solar Panel company it appeared a very exciting discovery but no news for must be two years.

[uk2day] 11/2/2019 11:54

If we come anywhere near discovery of new antibiotic these will skyrocket!!!

[fillipe] 11/2/2019 10:59

Coming up nicely, particular of late.

Much be one of their investee co's is perhaps coming to the boil.

f

[uk2day] 03/12/2018 16:13

Off to the races!!!!!

[uk2day] 13/11/2018 16:40

lots of late buying above the offer price today!, somethings cooking!!!

cant see your 40p support estimate ever being tested opodio!!

80p resistance to be tested more like!!

[uk2day] 06/11/2018 20:49

Lol, for a moment there I thought someone had some intelligent input on Fipp!

[opodio] 06/11/2018 19:24

Chart support at 40

[elgordo] 26/9/2018 18:06

Full page article on Alusid in the Times today. Doesn't say anything new, but good to see.

Link requires registration or subscription -

[uk2day] 22/9/2018 12:17

just what the doctor ordered!!! lol!


Frontier IP Group plc Amprologix to develop new antibiotics with Ingenza
20/09/2018 7:01am
RNS Non-Regulatory

TIDMFIPP

Frontier IP Group plc
20 September 2018
RNS Reach
AIM: FIPP
20 September 2018
Frontier IP Group Plc
("Frontier IP" or the "Group")
New Portfolio Company - Amprologix to develop new antibiotics to help combat antimicrobial resistance in partnership with Ingenza
Frontier IP, a specialist in commercialising university intellectual property, today announces it has taken a 10 per cent stake in Amprologix Limited ("the Company"), a spin-out from the University of Plymouth.
The company has been established to introduce new antibiotics, helping to tackle antimicrobial resistance, a major threat to human health globally. It will develop and commercialise the work of Dr Mathew Upton, Professor in Medical Microbiology at the University's School of Biomedical Sciences.
The first product from the Company is expected to be a cream containing epidermicin, one of the new antibiotics being developed to combat infections caused by antibiotic-resistant bacteria. Epidermicin can rapidly kill harmful bacteria including MRSA (methicillin resistant Staphylococcus aureus), Streptococcus and Enterococcus at very low doses, even if they are resistant to other antibiotics.
No new classes of antibiotics have been introduced into clinical use for the past 30 years, and the company is aiming to meet a growing need for new antibiotics as harmful microbes become increasingly drug resistant.
It has already secured industry involvement through a partnership with world-leading biotechnology and synthetic biology company Ingenza.
The new company is focused on four areas:
-- Developing epidermicin for commercial use
-- Discovering additional sources for new classes of antibiotics
-- Using Artificial Intelligence to improve antibiotic properties, working with Ingenza, IBM and the National Physical Laboratory
-- Developing efficient techniques to manufacture antibiotics at scale in partnership with Ingenza
In a relevant infection model, a single dose of epidermicin was as effective as six doses of the current standard of care. The antibiotic was initially recovered from a skin bacterium named Staphylococcus epidermidis, but can now be produced in a microbe suitable for industrial scale-up, using synthetic biology methods developed by Ingenza.
Professor Upton initially developed the patented technology working closely with UMI3 Ltd at The University of Manchester, which now takes a 13 per cent stake in the new business.
The World Health Organisation warned in February this year that "antibiotic resistance is one of the biggest threats to global health, food security, and development today".
A UK government review in 2015, chaired by economist Jim O'Neill, estimated that by 2050, the global cost of antibiotic resistance will rise to US$100 trillion and drug resistant infections will cause 10 million deaths a year, eclipsing the current toll from cancer and diabetes combined. The government estimates there are currently 5,000 deaths each year in the UK because antibiotics no longer work for some infections.
Neil Crabb, chief executive of Frontier IP, said: "We are delighted to work with Amprologix to commercialise these potentially life-saving antibiotics, and with a leading industrial partner in the area. It is further sign our business model is gaining traction with universities and industry alike."
Professor Mathew Upton, chief scientific officer of Amprologix, said: "It is very exciting to form a new company to take forwards our portfolio of novel antimicrobial compounds. Epidermicin, our lead candidate antibiotic, has excellent potential for treating and preventing serious, drug resistant infections. With our current team, the company will be the ideal vehicle to take epidermicin to the clinic."
Dr Ian Fotheringham, managing director of Ingenza, said: "This unique partnership fully exploits the synergy of Ingenza's versatile bio-manufacturing technologies and Amprologix's lead in discovering exciting new antimicrobial classes, spearheaded by Dr Upton's innovative research."
ENQUIRIES

[elgordo] 06/8/2018 18:03

Fieldwork Robotics agreement with Hall Hunter reported in today's The Times -

[fillipe] 04/7/2018 16:16

Not making the ducks fly off the water,currently.

f

[uk2day] 27/3/2018 22:54

Summary from todays results rns!


Frontier IP made good progress in pursuing growth and value for shareholders by:

· Generating value from our relationships through working on new spin-outs, significant equity holdings and licensing income

· Continuing to build a portfolio showing increasing signs of success

· Reviewing and extending our pipeline for sources of high-quality intellectual property

· Applying commercialisation expertise and leveraging our extensive network to help portfolio companies grow and achieve their business objectives

Performance

I am pleased to report we enjoyed an encouraging first half of the year across all areas of the business. Our core strategy is showing ever-more positive signs of delivering value and growth for our portfolio partners and shareholders. Fair value in our portfolio increased 19 per cent to £8,020,000 over the previous six months, representing year-on-year growth of 49 per cent.

Pre-tax profits increased 67% to £524,000; cash at £1.85 million.

Our continued growth was reflected in a highly successful capital markets day, held in Lisbon, Portugal, after the period end. This was attended by more than 70 participants including academics, industry, government, investors and a number of potential spin-out partners.

Results

Financial assets at fair value through profit and loss at 31 December 2017 increased to £8,020,000 (30 June 2017: £6,751,000; 31 December 2016: £5,396,000). Total revenue over the first half increased by 41% to £1,188,000 (2016: £843,000) reflecting the higher investment revaluations (unrealised) of £1,068,000 (2016: £711,000) while revenue from services decreased marginally to £120,000 (2016: £132,000). The profit before tax increased by 67% to £524,000 (2016: £314,000) reflecting the higher investment revaluations, partially offset by the higher administrative expenses. Administrative expenses increased by 26% to £667,000 (2016: £529,000) primarily reflecting increased staff, salaries and associated costs. Basic earnings per share was 1.17p (2016: 1.02p).

Cash balances stood at £1,849,000 as at 31 December 2017 (30 June 2017: £2,329,000; 31 December 2016: £186,000). Net assets per share as at 31 December 2017 were 32.0p (30 June 2017: 30.7p; 31 December 2016: 26.0p).

[uk2day] 27/3/2018 22:41

Mon, 26th Mar 2018 07:00
RNS Number : 8368I
Frontier IP Group plc
26 March 2018

Frontier IP Group plc

[26] March 2018

FIPP RNS Reach

Frontier IP Group Plc

("Frontier IP" or "the Group")

Team Expansion and London Office



Frontier IP Group, which specialises in intellectual property commercialisation, is pleased to announce it has appointed a communications professional to the team and is opening a new base in London. The moves provide a foundation for the next phase of the Group's growth.

We are delighted to welcome Andrew Johnson, who will have responsibility for communications and investor relations across the Group's activities. Andrew has more than 20 years' journalism experience and is a former Deputy City Editor of the Daily Express. He has also worked for RBS.

Andrew will be based in the City of London at our new offices at 18 King William Street, London, EC4N 7BP.

I somehow missed this rns yesterday?

I love the comment "The moves provide a foundation for the next phase of the Group's growth"

a share price rise from 14p-85p in last 5yrs is growth im already over the moon with!, makes one wonder what increase in value and earnings come from the new base opening in London?

and Fipp is still off the public radar! lol!

[uk2day] 22/2/2018 15:57

some nice chunky buys again today!!! something in the pipeline???

[uk2day] 19/2/2018 12:18

up we go!!!!!!